Inflammation exacerbates muscle destruction in Duchenne muscular dystrophy, and several investigators — including some on the International Space Station — are trying to block it
Inflammation — the immune system's first line of defense in tissue that's been damaged by injury or infection — is a good example of a process that's a good thing up to a point and under certain circumstances and a bad thing in excess or under the wrong circumstances.
MDA awarded $120,000 to Catabasis Pharmaceuticals to test two anti-inflammatory compounds, CAT-1004 and CAT-1040, in the mdx mouse model of Duchenne MD
The Muscular Dystrophy Association has awarded $120,000 to Cambridge, Mass.-based Catabasis Pharmaceuticals as part of a strategic partnership under which the pharmaceuticals company will test two compounds called CAT-1004 and CAT-1040 in the mdx research mouse model of Duchenne muscular dystrophy (DMD).
A variety of studies concerning myasthenia gravis (MG), a disease in which the immune system mistakenly attacks specialized parts of the junction between nerve and muscle cells, were presented at the 61st annual meeting of the American Academy of Neurology, held in Seattle April 25-May 2, 2009.
A report on drug development in neuromuscular diseases as of January 2009
In the era of molecular biology, the drug development process has moved from a “let’s try it and see what happens” approach to a scientifically based process of discovery and application.
For many of the diseases in MDA’s program, drug discovery begins with gene discovery — identifying a gene that, when flawed, causes a disease.